510(k) device
Alinity i STAT High Sensitivity Troponin-I
Abbott Laboratories Diagnostics Division · Immunoassay Method, Troponin Subunit (MMI, Class II) · First FDA decision May 19, 2022, newest May 4, 2023Heart attack (myocardial infarction)Heart attack and heart failure blood tests
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
3
Naming "Alinity i STAT"
MAUDE reports
614
Brand "Alinity i STAT", since 2015
PubMed studies
0
Mentioning "Alinity i STAT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Alinity i STAT High Sensitivity Troponin-I
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K230994 · Decided May 4, 2023 · 27 days after receipt
Device type: Immunoassay Method, Troponin Subunit (MMI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Alinity i STAT", any status and sponsor, newest update first.
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT06766435 · 42 participants · Start Jan 30, 2025 · Primary completion Mar 30, 2026
Device: i-STAT TBI Test · For: Traumatic Brain Injury
Sites: New York, New York · 3 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Alinity i STAT", and for the whole product code for context.
This brand
614 reports: 596 malfunction, 18 injury, 0 death
Whole product code MMI
7,546 reports: 7,009 malfunction, 528 injury, 4 death
Newest reports for this brand
Abbott Ireland Diagnostics Division
3005094123-2026-00533 · Received Oct 27, 2026 · Event dated Oct 7, 2026
Device type: Immunoassay Method, Troponin Subunit (MMI)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Alinity i STAT"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MMI.
- Access hsTnIBeckman Coulter, Inc. · 510(k) 2025
- Elecsys Troponin T Gen 5Roche Diagnostics · 510(k) 2021
- i-STAT hs-TnI cartridge with the i-STAT Alinity SystemAbbott Point of Care, Inc. · 510(k) 2026
- VITROS Immunodiagnostic Products hs Troponin I Reagent PackOrtho-Clinical Diagnostics, Inc. · 510(k) 2025
- Atellica® IM High-Sensitivity Troponin I (TnIH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2024
- Vidas Troponin I Ultra (Tniu) Assay, Model 30 448bioMerieux, Inc. · 510(k) 2007
- Dimension Vista Ctni Flex Reagent CartridgeDade Behring, Inc. · 510(k) 2007
- Abbott Axsym Troponin-I AdvAbbott Laboratories · 510(k) 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.